DongKoo Bio & Pharma Co., Ltd.
Financials
Valuation Metrics
DongKoo Bio & Pharma Co., Ltd.'s Market Cap is ₩1002B. At end of 2025 it was ₩1557B. Ranked #1284 of 2,421 in KR market (top 53%), #703 of 1,640 on KOSDAQ (top 43%), #141 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 61%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 100.20B KRW | KR#1,284/2,421 Sec#141/231 |
| Revenue | 241.43B KRW | KR#932/2,421 Sec#52/231 |
| Net Income | 32.88B KRW | KR#533/2,421 Sec#33/231 |
| Total Assets | 318.60B KRW | KR#1,000/2,421 Sec#64/231 |
| Net Assets | 142.58B KRW | KR#1,171/2,421 Sec#86/231 |
| Employees | 418 | KR#584/2,421 Sec#48/231 |
| Value | ||
| P/E | 3.05x | KR#158/2,421 Sec#6/231 |
| P/B | 0.70x | KR#1,126/2,421 Sec#64/231 |
| P/S | 0.41x | KR#795/2,421 Sec#29/231 |
| EV/EBITDA | 599.18x | KR#1,557/2,421 Sec#111/231 |
| FCF Yield | -21.90% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 23.06% | KR#128/2,421 Sec#11/231 |
| ROA | 10.32% | KR#256/2,421 Sec#19/231 |
| Op. Margin | 0.14% | KR#1,593/2,421 Sec#111/231 |
| Revenue Growth | -0.46% | KR#1,556/2,421 Sec#154/231 |
| Financial Health | ||
| Debt Ratio | 123.46% | KR#1,739/2,421 Sec#194/231 |
| Total Debt | 121.32B KRW | KR#663/2,421 Sec#40/231 |
| FCF | -21.94B KRW | KR#1,910/2,421 Sec#182/231 |
| Cash | 18.37B KRW | KR#1,297/2,421 Sec#99/231 |
| Current Ratio | 0.90x | KR#1,840/2,421 Sec#177/231 |
| Dividend | ||
| Div. Yield | 3.42% | KR#547/2,421 Sec#22/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -30.57% | KR#1,574/2,421 Sec#127/231 |
| 1M Return | -2.36% | KR#1,504/2,421 Sec#118/231 |
| From 52W High | -44.91% | KR#1,160/2,421 Sec#88/231 |
| 1Y MDD | -43.35% | KR#706/2,421 Sec#54/231 |
| Trading | ||
| Volume | 25,994 shares | KR#1,457/2,421 Sec#146/231 |
| Trading Value | 91.2M KRW | KR#1,597/2,421 Sec#157/231 |
| Foreign Own. | 1.45% | KR#1,845/2,421 Sec#181/231 |
| Per Share | ||
| EPS | 1,155 KRW | KR#663/2,421 Sec#43/231 |
| BPS | 5,009 KRW | KR#1,491/2,421 Sec#106/231 |
Company Info
Established in 1983 for the manufacturing and sale of finished pharmaceuticals, the company was listed on KOSDAQ in 2018 and holds 5 consolidated subsidiaries, including Loftyrock Investment. It operates a four-business unit system: Pharmaceuticals, focusing on manufacturing and selling professional pharmaceuticals and quasi-drugs; Finance; Medical Services; and Pharmaceutical Wholesale and Consulting. The company maintains its #1 position in dermatology prescriptions, possesses differentiated manufacturing technology, and is actively pursuing entry into the cosmeceutical market and overseas expansion.